Data Sharing Statement

Teng. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease. *JAMA Neurol*. Published June 13, 2022. doi:10.1001/jamaneurol.2022.1375

Data

Data available: Yes

Data types: Deidentified participant data How to access data: https://vivli.org/ When available: With publication

Supporting Documents
Document types: None

Additional Information

Who can access the data: Qualified researchers Types of analyses: Approved secondary analyses

Mechanisms of data availability: Signed data access agreement